Streetbeat News

Stock Prices

SNY

Sanofi announced that the one-year follow-up from the Phase 2 study of Riliprubart showed efficacy and safety, with rapid and durable reduction of key biomarkers, including those associated with the classical complement pathway and nerve cell damage.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 10:49 am

LUV

Southwest Airlines shares are trading lower after the company lowered its Q2 unit revenues outlook.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 10:42 am

SFTBY

TEM

SoftBank Group plans to launch an AI-powered medical service in Japan through a joint venture with Tempus AI Inc. The venture, capitalized at $188 million, will be equally owned by both companies and aims to start operations by July. Tempus AI's stock surged nearly 3% in pre-market trading following the news.

Portfolio Pulse from Benzinga Neuro

June 26, 2024 | 10:42 am

LUV

Southwest Airlines expects an all-time quarterly record for operating revenue in Q2 2024, despite lowered unit revenue expectations. The company will provide more details in its upcoming financial results and at Investor Day in September 2024.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 10:38 am

LUV

Southwest Airlines reports strong Q2 operational performance with minimal cancellations, achieving a 99.5% completion factor despite challenging weather. However, the company has reduced its RASM expectations due to complexities in adapting its revenue management to current booking patterns.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 10:36 am

LUV

Southwest Airlines has revised its Q2 operating revenue per available seat mile (RASM) expectations to a decline of 4.0% to 4.5%, compared to the previous forecast of a 1.5% to 3.5% decline.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 10:34 am

BEAM

Beam Therapeutics announced the first patient treatment with BEAM-302, an investigational in vivo base editing medicine for severe Alpha-1 Antitrypsin Deficiency, currently in a Phase 1/2 trial.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 10:34 am

TSLA

Tesla, Inc. (NASDAQ:TSLA) is set to unveil its robotaxi on Aug. 8, but fund manager Gary Black suggests that the service won't take off until Tesla's full self-driving technology is fully unsupervised. An influencer's analysis shows potential revenue of $1.4 billion annually if Tesla subsidizes rides and requires drivers to use Tesla vehicles. Black believes that without discounted pricing, Tesla's supervised ride-hailing service won't compete effectively with Uber and Lyft.

Portfolio Pulse from Shanthi Rexaline

June 26, 2024 | 10:34 am

SVRA

Savara Inc. (NASDAQ:SVRA) announced positive results from its Phase 3 IMPALA-2 clinical trial for molgramostim in treating a rare respiratory disease. The trial met its primary and several secondary endpoints, showing significant efficacy and safety.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 10:33 am

SVRA

Savara's Phase 3 IMPALA-2 trial of Molgramostim met statistical significance for primary and multiple secondary endpoints in treating autoimmune pulmonary alveolar proteinosis. The company plans to complete BLA submission in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 10:33 am